Published in Medicine and Law Weekly, November 14th, 2008
The Panel found that most of the packages accused by Tessera are not subject to the patent royalty provisions of the license. The Panel ordered that damages for past royalties for infringing packages from March 2002 through March 2008 be apportioned using percentages set by the Panel on a product "family by family" basis for sales with a U.S. nexus, subject to certain offsets. The Panel has ordered...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly